Immunotherapy for clinically isolated syndrome? Not necessarily...

Nature Clinical Practice Neurology

Volumn 4, Issue 5, 2008, Pages 236-237

  Siva, Aksel ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; PLACEBO;

ARTICLE; CLINICAL TRIAL; CLINICALLY ISOLATED SYNDROME; DEMYELINATING DISEASE; DISEASE COURSE; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PRIORITY JOURNAL; PROGNOSIS; SYMPTOM; TREATMENT PLANNING;

HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; SYNDROME;

EID: 43149093961     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0774     Document Type: Article

References (11)

1. Frohman EM et al. (2006) Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 63: 614-619
2. Comi G and Martino G (2006) MS treatment: New perspectives. Clin Neurol Neurosurg 108: 339-345
3. Siva A (2006) The spectrum of multiple sclerosis and treatment decisions. Clin Neurol Neurosurg 108: 333-338
4. De Stefano N et al. (2006) Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Ann Neurol 59: 634-639
5. Haghighi S et al. (2004) Cerebrospinal fluid markers in MS patients and their healthy siblings. Acta Neurol Scand 109: 97-99
6. acobs LD et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343: 898-904
7. Comi G et al. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomized study. Lancet 357: 1576-1582
8. Kappos L et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67: 1242-1249
9. Pittock SJ et al. (2006) Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol 63: 611-614
10. Fillipini G and Ebers G (2007) Multiple sclerosis: Critical review of evidence for each question. In Evidence-based Neurology: Management of Neurological Disorders, 221-233 (Eds Candelise L: et al.) Oxford: Blackwell BM Books
11. Kappos L et al. (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet 370: 389-397